title: Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.
abstract: Vitronectin (Vtn) is a glycoprotein found in normal serum and pathological extracellular matrix. Given its known interactions with plasminogen activator inhibitor-1 (PAI-1) and Vtn cellular receptors, especially αvβ3 integrin and the urokinase receptor (uPAR), this study was designed to investigate its role in renal fibrogenesis in the mouse model of unilateral ureteral obstruction (UUO). Kidney Vtn mRNA levels were increased ×1.8-5.1 and Vtn protein levels ×1.9-3 on days 7, 14, and 21 after UUO compared with sham kidney levels. Groups of age-matched C57BL/6 wild-type (Vtn+/+) and Vtn-/- mice (n = 10-11/group) were killed 7, 14, or 21 days after UUO. Absence of Vtn resulted in the following significant differences, but only on day 14: fewer αSMA+ interstitial myofibroblasts (×0.53), lower procollagen III mRNA levels (×0.41), lower PAI-1 protein (×0.23), higher uPA activity (×1.1), and lower αv protein (×0.32). The number of CD68+ macrophages did not differ between the genotypes. Despite these transient differences on day 14, the absence of Vtn had no effect on fibrosis severity based on both picrosirius red-positive interstitial area and total kidney collagen measured by the hydroxyproline assay. These findings suggest that despite significant interstitial Vtn deposition in the UUO model of chronic kidney disease, its fibrogenic role is either nonessential or redundant. These data are remarkable given Vtn's strong affinity for the potent fibrogenic molecule PAI-1.
authors.affiliation: Seattle Children’s Research Institute, Department of Pediatrics, University of Washington, USA.
authors.forename: Jesús M
authors.initials: JM
authors.lastname: López-Guisa
authors.forename: Allen C
authors.initials: AC
authors.lastname: Rassa
authors.forename: Xiaohe
authors.initials: X
authors.lastname: Cai
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Collins
authors.forename: Allison A
authors.initials: AA
authors.lastname: Eddy
mesh_terms: D000818:Animals; D002908:Chronic Disease; D004195:Disease Models, Animal; D005355:Fibrosis; D005838:Genotype; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D007674:Kidney Diseases / Q000209:etiology* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D058628:Myofibroblasts / Q000378:metabolism* / Q000473:pathology; D010641:Phenotype; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D010960:Plasminogen Activators / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D055293:Receptors, Urokinase Plasminogen Activator / Q000378:metabolism; D013997:Time Factors; D015854:Up-Regulation; D014517:Ureteral Obstruction / Q000150:complications* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D014746:Vimentin / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*
chemical_list: D039302:Integrin alphaVbeta3; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D055293:Receptors, Urokinase Plasminogen Activator; D014746:Vimentin; D010960:Plasminogen Activators